ClinicalTrials.gg
CompletedNCT05932277Updated Oct 30, 2023

A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants

A Phase 1 interventional study of BMS-986419 and Caffeine in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-30.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2023, 3 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the effect of BMS-986419 on the pharmacokinetics (PK) of single doses of caffeine (CYP1A2 substrate), bupropion (CYP2B6 substrate), midazolam (CYP3A4 substrate), flurbiprofen (CYP2C9 substrate), omeprazole (CYP2C19 substrate), and fexofenadine (P-gp substrate), in healthy participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • healthy
  • pharmacokinetics
  • BMS-986419
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female participants without deviation from normal in medical history, physical examination (PE), (ECG), and clinical laboratory determinations (congenital nonhemolytic hyperbilirubinemia [eg, suspicion of Gilbert's syndrome based on total and direct ] is not acceptable) at screening and check-in (Day -1).
  • (BMI) of 18 to 32 kg/m2, inclusive, and total body weight ≥ 50 kg. BMI may be rounded.

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical conditions or any significant acute or chronic medical illness as determined by the investigator
  • Any major surgery within 30 days of study intervention administration, such as gastrointestinal surgery that could impact the absorption of study intervention

Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Cocktail Probe Substrates + BMS-986419

    Drug: BMS-986419 · Drug: Caffeine · Drug: Bupropion · Drug: Flurbiprofen · Drug: Omeprazole · Drug: Midazolam · Drug: Fexofenadine

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to Day 25

  2. Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T))

    Time frame: Up to Day 25

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))

    Time frame: Up to Day 25

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to Day 25

  2. Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T))

    Time frame: Up to Day 25

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))

    Time frame: Up to Day 25

  4. Number of participants with Adverse Events (AEs)

    Time frame: Up to 28 days after last dose

  5. Number of participants with Serious Adverse Events (SAEs)

    Time frame: Up to 28 days after last dose

  6. Number of participants with AEs leading to discontinuation

    Time frame: Up to 28 days after last dose

  7. Number of participants with vital sign abnormalities

    Time frame: Up to Day 25

  8. Number of participants with 12-lead ECG assessment abnormalities

    Time frame: Up to Day 25

  9. Number of participants with physical examination abnormalities

    Time frame: Up to Day 25

  10. Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to Day 25

  11. Number of participants with clinical laboratory abnormalities

    Time frame: Up to Day 25

07

Study locations

1 site
  • ICON Lenexa
    Lenexa, Kansas 66219, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Sep 2023, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2023
First posted
Jul 6, 2023
StartActual
Jun 29, 2023
Primary completionActual
Sep 13, 2023
CompletionActual
Sep 13, 2023
Last update
Oct 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05932277
Responsible party
Sponsor
First posted
Jul 6, 2023
Start date
Jun 29, 2023
Primary completion
Sep 13, 2023
Completion
Sep 13, 2023
Last update
Oct 30, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Comtifator

Start the discussion